A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Clinical trial NCT03912064 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03912064
Sponsor: Dana-Farber Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Myelodysplastic Syndromes Myeloproliferative Neoplasms Chronic Myelomonocytic Leukemia Myelofibrosis

Start date: 2019-07-10
Primary completion: 2024-05-24
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.